lenalidomide has been researched along with cediranib in 4 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (cediranib) | Trials (cediranib) | Recent Studies (post-2010) (cediranib) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 279 | 102 | 204 |
| Protein | Taxonomy | lenalidomide (IC50) | cediranib (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.005 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.026 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.036 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.005 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.003 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Cohen, EEW; de Souza, JA; Hayes, DN; Karrison, T; Krzyzanowska, MK; Liao, CY; Libao, B; Prescott, K; Rosenberg, AJ; Saloura, V; Schechter, RB; Seiwert, TY; Stadler, WM; Villaflor, VM; Vokes, EE; Winquist, E; Worden, FP | 1 |
2 review(s) available for lenalidomide and cediranib
| Article | Year |
|---|---|
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
1 trial(s) available for lenalidomide and cediranib
| Article | Year |
|---|---|
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Topics: Adenocarcinoma; Humans; Infant; Iodine Radioisotopes; Lenalidomide; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2023 |
1 other study(ies) available for lenalidomide and cediranib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |